drugset / Trial / NCT05486026

Efficacy of Duloxetine Compared to NSIADs in Osteoarthritis of Knee

NCT05486026

Phase 2 Completed 200 enrolled Hawler Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

Osteoarthritis (OA) is the most common degenerative joint disease, affecting more than 25% of the population . Knee OA is an insidious disease related to structural changes in the joint over many years. Progressive articular damage results in a loss of the extracellular matrix of cartilage in addition to changes in subchondral bone. Duloxetine, a selective serotonin, and norepinephrine reuptake inhibitor, it seems to be effective in treating neuropathic and chronic pain conditions.

Timeline

Start
2022-08-20
Primary completion
2022-12-29
Completion
2023-01-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Duloxetine Small molecule 30 mg

Indications